Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30147933 | 1.00 | ALDH1A1 (0.34) | ALDH1A1 | |
| SCHEMBL2512408 | 0.83 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL316864 | 0.79 | DPP4 (0.30) | — | |
| SCHEMBL9456026 | 0.79 | — | — | |
| SCHEMBL30624461 | 0.79 | — | — | |
| SCHEMBL667046 | 0.77 | CCR5 (0.33) | — | |
| SCHEMBL4062005 | 0.76 | — | — | |
| SCHEMBL30297897 | 0.76 | ALDH1A1 (0.36) | ALDH1A1 | |
| SCHEMBL317432 | 0.76 | ALDH1A1 (0.36) | ALDH1A1 | |
| SCHEMBL714904 | 0.76 | PTGS1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107663192-B | A kind of preparation method of Rabeprazole impurity | 梯尔希（南京）药物研发有限公司 | 2019-05-10 | — | — | CN | claimed |
| CN-107663192-A | A kind of preparation method of Rabeprazole impurity | 梯尔希（南京）药物研发有限公司 | 2018-02-06 | — | — | CN | claimed |
| CN-106083705-A | The preparation method of 2 methylol 4 (methoxy propoxy) 3 methyl pyridinium chloride | 上药康丽（常州）药业有限公司 | 2016-11-09 | — | — | CN | claimed |
| CN-102838537-B | Preparation method of lansoprazole intermediate | Shouguang fukang pharmaceutical co ltd | 2014-04-09 | — | — | CN | claimed |
| US-8513427-B2 | Compounds for producing substituted sulfoxides, process for producing the same and use thereof | MATRIX LABORATORIES LIMITED (IN) | 2013-08-20 | — | — | US | claimed |
| EP-2342193-B1 | NOVEL COMPOUNDS FOR PRODUCING SUBSTITUTED SULFOXIDES, PROCESS FOR PRODUCING THE SAME AND USE THEREOF | MATRIX LAB LTD (IN) | 2013-06-05 | — | — | EP | claimed |
| US-20110184182-A1 | COMPOUNDS FOR PRODUCING SUBSTITUTED SULFOXIDES, PROCESS FOR PRODUCING THE SAME AND USE THEREOF | MATRIX LABORATORIES LIMITED (IN) | 2011-07-28 | — | — | US | claimed |
| WO-2025085783-A1 | PRAZOLE-BASED ANTIVIRAL THERAPEUTICS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2025-04-24 | — | — | WO | disclosed |
| WO-2024059204-A1 | HETEROARYL ANALOGS AS MGLU5 NEGATIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING THE SAME | VANDERBILT UNIVERSITY (US) | 2024-03-21 | — | — | WO | disclosed |
| EP-3807266-B1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-25 | — | — | EP | disclosed |
| CN-112585128-B | Pyrazole derivatives as MALT1 inhibitors | 詹森药业有限公司 | 2023-02-21 | — | — | CN | disclosed |
| WO-2022262143-A1 | METHOD FOR PREPARING PYRIDINE BORATE | 杭州中美华东制药有限公司 | 2022-12-22 | — | — | WO | disclosed |
| WO-2021242807-A1 | METHODS FOR PREPARING METHYL (S)-2-AMINO-3-(4-(2,3-DIMETHYLPYRIDIN-4-YL)PHENYL)PROPIONATE AND HYDROCHLORIC ACID SALTS THEREOF | VTV THERAPEUTICS LLC (US) | 2021-12-02 | — | — | WO | disclosed |
| CN-1018923-B | Process for preparing pyridine derivatives having antiulcer activity | EISAI CO LTD (JP) | 1992-11-04 | — | — | CN | disclosed |
| EP-0475456-A1 | Pyridine derivatives, pharmaceutical compositions comprising the same, the use of the same for the manufacture of medicaments having therapeutic or preventative value, and a process for preparing the same | Eisai Co., Ltd. (JP) | 1992-03-18 | — | — | EP | disclosed |
| US-5045552-A | Pyridine derivatives having anti-ulcerative activity | EISAI CO., LTD. (JP) | 1991-09-03 | — | — | US | disclosed |
| EP-0295603-A1 | Benzimidazol derivatives and therapeutic agent for ulcer comprising the same | Eisai Co., Ltd. (JP) | 1988-12-21 | — | — | EP | disclosed |
| EP-0268956-A2 | Pyridine derivatives, pharmaceutical compositions comprising the same, the use of the same for the manufacture of medicaments having therapeutic or preventative value, and a process for preparing the same | Eisai Co., Ltd. (JP) | 1988-06-01 | — | — | EP | disclosed |
| CN-87107777-A | Pyridine derivate with antiulcer activity | — | 1988-06-01 | — | — | CN | disclosed |
| EP-0167943-A2 | Benzimidazole derivatives, process for their preparation, and their use as pharmaceuticals | BEECHAM GROUP PLC (GB) | 1986-01-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110184182-A1 | COMPOUNDS FOR PRODUCING SUBSTITUTED SULFOXIDES, PROCESS FOR PRODUCING THE SAME AND USE THEREOF | SQOR, SMOX, CBS | ALDH1A1 248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.